FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled the release of its fourth quarter and full year 2024 financial results for Monday, March 17, 2025, after market close. The company will host a conference call at 5:00 PM Eastern Time on the same day, featuring a presentation by the management team followed by a live Q&A session to discuss corporate and financial performance.
FibroGen (NASDAQ: FGEN) ha programmato la pubblicazione dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per lunedì 17 marzo 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 17:00 ora orientale dello stesso giorno, con una presentazione del team di gestione seguita da una sessione di domande e risposte dal vivo per discutere le performance aziendali e finanziarie.
FibroGen (NASDAQ: FGEN) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el lunes 17 de marzo de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 5:00 PM, hora del Este el mismo día, que incluirá una presentación del equipo directivo seguida de una sesión de preguntas y respuestas en vivo para discutir el desempeño corporativo y financiero.
FibroGen (NASDAQ: FGEN)은 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 17일 월요일 시장 종료 후로 예정했습니다. 회사는 같은 날 동부 표준시 오후 5시에 경영진의 발표와 함께 기업 및 재무 성과에 대한 질의응답 세션이 포함된 컨퍼런스 콜을 개최할 예정입니다.
FibroGen (NASDAQ: FGEN) a prévu la publication de ses résultats financiers pour le quatrième trimestre et l'année complète 2024 pour le lundi 17 mars 2025, après la fermeture du marché. L'entreprise organisera une conférence téléphonique à 17h00, heure de l'Est le même jour, comprenant une présentation de l'équipe de direction suivie d'une session de questions-réponses en direct pour discuter de la performance de l'entreprise et des finances.
FibroGen (NASDAQ: FGEN) hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Montag, den 17. März 2025, nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz veranstalten, die eine Präsentation des Managements gefolgt von einer Live-Q&A-Session zur Diskussion der Unternehmens- und Finanzleistung umfasst.
- None.
- None.
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When will FibroGen (FGEN) release Q4 and full year 2024 earnings?
What time is FibroGen's (FGEN) Q4 2024 earnings call?
How can investors access FibroGen's (FGEN) Q4 2024 earnings call?
Will FibroGen's (FGEN) Q4 2024 earnings call be available for replay?
